Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,820 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model.
Ito A, Ishida T, Yano H, Inagaki A, Suzuki S, Sato F, Takino H, Mori F, Ri M, Kusumoto S, Komatsu H, Iida S, Inagaki H, Ueda R. Ito A, et al. Among authors: sato f. Cancer Immunol Immunother. 2009 Aug;58(8):1195-206. doi: 10.1007/s00262-008-0632-0. Epub 2008 Dec 2. Cancer Immunol Immunother. 2009. PMID: 19048251 Free PMC article.
Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo.
Ito A, Ishida T, Utsunomiya A, Sato F, Mori F, Yano H, Inagaki A, Suzuki S, Takino H, Ri M, Kusumoto S, Komatsu H, Iida S, Inagaki H, Ueda R. Ito A, et al. Among authors: sato f. J Immunol. 2009 Oct 1;183(7):4782-91. doi: 10.4049/jimmunol.0900699. Epub 2009 Sep 11. J Immunol. 2009. PMID: 19748990 Clinical Trial.
A complement-dependent cytotoxicity-enhancing anti-CD20 antibody mediating potent antitumor activity in the humanized NOD/Shi-scid, IL-2Rγ(null) mouse lymphoma model.
Sato F, Ito A, Ishida T, Mori F, Takino H, Inagaki A, Ri M, Kusumoto S, Komatsu H, Iida S, Okada N, Inagaki H, Ueda R. Sato F, et al. Cancer Immunol Immunother. 2010 Dec;59(12):1791-800. doi: 10.1007/s00262-010-0905-2. Epub 2010 Aug 17. Cancer Immunol Immunother. 2010. PMID: 20714721 Free PMC article.
Tax is a potential molecular target for immunotherapy of adult T-cell leukemia/lymphoma.
Suzuki S, Masaki A, Ishida T, Ito A, Mori F, Sato F, Narita T, Ri M, Kusumoto S, Komatsu H, Fukumori Y, Nishikawa H, Tanaka Y, Niimi A, Inagaki H, Iida S, Ueda R. Suzuki S, et al. Among authors: sato f. Cancer Sci. 2012 Oct;103(10):1764-73. doi: 10.1111/j.1349-7006.2012.02371.x. Epub 2012 Aug 13. Cancer Sci. 2012. PMID: 22735080 Free PMC article.
Angioimmunoblastic T-cell lymphoma mice model.
Sato F, Ishida T, Ito A, Mori F, Masaki A, Takino H, Narita T, Ri M, Kusumoto S, Suzuki S, Komatsu H, Niimi A, Ueda R, Inagaki H, Iida S. Sato F, et al. Leuk Res. 2013 Jan;37(1):21-7. doi: 10.1016/j.leukres.2012.09.009. Epub 2012 Sep 29. Leuk Res. 2013. PMID: 23026775
Antitumor effects of bevacizumab in a microenvironment-dependent human adult T-cell leukemia/lymphoma mouse model.
Mori F, Ishida T, Ito A, Sato F, Masaki A, Narita T, Suzuki S, Yamada T, Takino H, Ri M, Kusumoto S, Komatsu H, Hishizawa M, Imada K, Takaori-Kondo A, Niimi A, Ueda R, Inagaki H, Iida S. Mori F, et al. Among authors: sato f. Eur J Haematol. 2014 Mar;92(3):219-28. doi: 10.1111/ejh.12231. Epub 2013 Nov 26. Eur J Haematol. 2014. PMID: 24188416
1,820 results